Pulnovo Medical annonce les résultats de l'essai PADN-HF-PH lors du congrès de l'ESC 2026 ; ceux-ci sont publiés simultanément dans le New England Journal of Medicine (NEJM)
Data ReadoutpositivePositive
AI Analysis
Summary
Pulnovo Medical announced positive results from the PADN-HF-PH trial in 264 patients with pulmonary hypertension associated with left heart failure, demonstrating a 51% reduction in clinical worsening risk. Results were presented at ESC 2026 and simultaneously published in the New England Journal of Medicine.
Clinical Trial Data
Primary Endpoint
Met
Patients
264
Outcome Details
PADN-HF-PH trial showed 51% reduction in clinical worsening risk and 35.5% reduction in recurrent clinical events in 264 patients with PH-LHD
Importance:8/10
Sentiment:
0.85
Phase 3Clinical Trial ResultsPulmonary HypertensionHeart FailureESC 2026 ConferenceNEJM Publication
Read the original article
Published by PR Newswire Pharma on September 3, 2026 8:08 PM